To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The primary objective of this trial is to investigate the safety and tolerability of BI 1467335 in healthy male and female subjects following oral administration of multiple rising doses over 28 days. Secondary objectives are the exploration of the pharmacokinetics (PK) and target engagement biomarkers of BI 1467335 after multiple dosing.
Epistemonikos ID: 753cff8758902182a7a15353ecc1937f762b55fa
First added on: May 12, 2024